NCT06888362 2026-01-28
Trial to Investigate GZ21T in Healthy Volunteers
Genzada Pharmaceuticals USA, Inc.
Phase 1 Completed
Clinical Trials
24 trialsNCT07318675 2026-01-06
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1 Recruiting
NCT01449513 2025-03-07
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
LEO Pharma
Phase 1 Completed
NCT01387711 2025-02-24
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
LEO Pharma
Phase 1 Completed
NCT01703078 2025-02-24
Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis
LEO Pharma
Phase 1 Completed
NCT01892137 2025-02-24
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
LEO Pharma
Phase 1 Completed
NCT02124239 2025-02-24
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
LEO Pharma
Phase 1 Completed
NCT02424305 2025-02-24
Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
LEO Pharma
Phase 1 Completed
NCT02600598 2025-02-24
Biological Effects of LEO 43204 in Actinic Keratosis
LEO Pharma
Phase 1 Completed
NCT02650505 2025-02-24
A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel
LEO Pharma
Phase 1 Completed
NCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT04319159 2021-11-11
Study to Evaluate the Safety of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT03575780 2019-12-09
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
Athenex, Inc.
Phase 1 Completed
NCT02559934 2019-07-15
Multiple-dose Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis
G&E Herbal Biotechnology Co., LTD
Phase 1 Completed
NCT02337205 2018-07-06
Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis
Athenex, Inc.
Phase 1 Completed
NCT00659893 2015-09-14
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
Peplin
Phase 1 Completed
NCT01302925 2015-09-14
PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects
Peplin
Phase 1 Completed
NCT00850681 2015-09-09
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT00850811 2015-09-09
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT02029066 2015-08-13
Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis
G&E Herbal Biotechnology Co., LTD
Phase 1 Completed
NCT00544258 2015-02-12
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
Peplin
Phase 1 Completed
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01742663 2014-01-22
A Study Comparing Diclofenac Sodium Gel 3% to SolarazeĀ® Gel 3% in the Treatment of Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01788007 2014-01-22
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed